Induction of glucose intolerance by acute administration of rimonabant

Pharmacology

Volumn 89, Issue 5-6, 2012, Pages 339-347

  Mandhane, Sanjay ^a   Nayak, Prasanta ^a   Soni, Durgesh ^a   Jain, Shakti ^a   Ashton, John C ^b   Rajamannar, Thennati ^a  

^a Sun Pharma Advanced Research Company Limited   (India)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

5 Hydroxytryptophan; Cannabinoids; Dopamine; Glucose tolerance; Insulin; Rimonabant; WIN55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 HYDROXYTRYPTOPHAN; DOPAMINE; FENCLONINE; GLUCOSE; HALOPERIDOL; INSULIN; ONDANSETRON; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FOOD INTAKE; GASTROINTESTINAL TRANSIT; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; INSULIN BLOOD LEVEL; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIVER CELL; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BENZOXAZINES; BLOOD GLUCOSE; DOPAMINE ANTAGONISTS; EATING; FENCLONINE; GLUCOSE; GLUCOSE INTOLERANCE; HALOPERIDOL; HEPATOCYTES; INFUSIONS, INTRAVENTRICULAR; INSULIN; MALE; MICE; MORPHOLINES; NAPHTHALENES; ONDANSETRON; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 84861894716     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000337731     Document Type: Article

References (39)

1. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D: SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-244.
2. Pertwee RG: Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147:S163-S171.
3. McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, Betz AJ, IshiwariK, Makriyannis A, Salamone JD: The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and foodreinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003; 14: 583.
4. Gadde KM: Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction. Curr Drug Targets Cardiovasc Hematol Disord2005; 5: 549-556.
5. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, Martin BR:CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005; 145: 293-300.
6. Després JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121.
7. Bermúdez-Silva FJ, Serrano A, Diaz-Molina FJ, Sánchez Vera I, Juan-Pico P, Nadal A, Fuentes E, Rodríguez de Fonseca F: Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531: 282-284.
8. Bermudez-Silva FJ, Sanchez-Vera I, Suárez J, Serrano A, Fuentes E, Juan-Pico P, Nadal A, Rodríguez de Fonseca F: Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565: 207-211.
9. Izzo AA, Sharkey KA: Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126: 21-38.
10. Horowitz M, Edelbroek MAL, Wishart JM, Straathof JW: Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36: 857-862.
11. Darmani NA, Janoyan JJ, Kumar N, Crim JL: Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 2003; 75: 777-787.
12. Griebel G, Stemmelin J, Scatton B: Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005; 57: 261-267.
13. Haley TJ, McCormick WG: Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 1957; 12: 12.
14. Pharmacopoeia US: United States Pharmacopoeia and National Formulary (USP 34-NF 29). Rockville, United States Pharmacopoeia Convention, 2011, vol 2, pp 2977-2979.
15. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612.
16. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME: Atypical responsiveness of the orphan receptor gpr55 to cannabinoid ligands. J Biol Chem 2009; 284: 29817-29827.
17. Romero-Zerbo SY, Rafacho A, Diaz-Arteaga A, Suarez J, Quesada I, Imbernon M, Ross RA, Dieguez C, Rodriguez de Fonseca F, Nogueiras R, Nadal A, Bermudez-Silva FJ: A role for the putative cannabinoid receptor gpr55 in the islets of langerhans. J Endocrinol 2011; 211: 177-185.
18. Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M: Vanilloid VR1 receptor is involvedin rimonabant-induced neuroprotection. Br J Pharmacol 2006; 147: 552-559.
19. Akiba Y, Kato S, Katsube K, Nakamura M, Takeuchi K, Ishii H, Hibi T: Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats. Biochem Biophys Res Commun 2004; 321: 219-225.
20. Fong T, Shearman L, Stribling D, Shu J, Lao J, Huang CRR, Xiao J, Shen CP, Tyszkiewicz J, Strack A: Pharmacological efficacy and safety profile of taranabant in preclinical species. Drug Dev Res 2009; 70: 349-362.
21. Juan-Picó P, Fuentes E, Javier BS: Cannabinoid receptors regulate Ca 2+ signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006; 39: 155-162.
22. Getty-Kaushik L, Richard AMT, Deeney JT, Krawczyk S, Shirihai O, Corkey BE: The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity 2009; 17: 1856-1860.
23. Gin H, Rigalleau V: Post-prandial hyperglycemia. Post-prandial hyperglycemia and diabetes. Diabet Metab 2000; 26: 265-272.
24. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S: The CB1 receptor antagonist rimonabant reverses the dietinduced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567-1569.
25. Lichtman AH, Cravatt BF: Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005; 115: 1130-1133.
26. Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, Muller G, Schmoll D, Kramer W: CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 2007; 293:E826.
27. Schwartz JG, Guan D, Green GM, Phillips WT: Treatment with an oral proteinase inhibitorslows gastric emptying and acutely reduces glucose and insulin levels after a liquid meal in type II diabetic patients. Diabetes Care 1994; 17: 255.
28. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L: Gastric emptying inearly noninsulin-dependent diabetes mellitus.J Nucl Med 1996; 37: 1643.
29. Shiroyama K, Moriwaki K, Yuge O: The direct effect of dopamine on glucose release from primary cultured rat hepatocytes. In Vivo 1998; 12: 527.
30. Durant S, Coulaud J, Homo-Delarche F: Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. Rev Diabet Stud 2007; 4: 185.
31. Nonogaki K, Iguchi A: Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 1997; 60: 797-807.
32. Hsiao SH, Chung HH, Inui A, Tong YC, Cheng JT: Inhibitory effect of 5-hydroxytryptamine on hyperphagia in mice with genetic overexpression of neuropeptide Y. Neurosci Lett 2006; 394: 256-258.
33. Chaouloff F, Laude D, Baudrie V: Ganglionic transmission is a prerequisite for the adrenaline-releasing and hyperglycemic effects of 8-OH-DPAT. Eur J Pharmacol 1990; 185: 11-18.
34. Carvalho F, Macedo D, Bandeira I, Maldonado I, Salles L, Azevedo MF, Rocha MA, Fregoneze JB, De Castro-e-Silva E: Central 5-HT 3 receptor stimulation by m-CPBG increases blood glucose in rats. Horm Metab Res 2002; 34: 55-61.
35. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, Morris HA, Horowitz M: Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3431.
36. Matsuda H, Li Y, Yamahara J, Yoshikawa M: Inhibition of gastric emptying by triterpenesaponin, momordin Ic, in mice: roles of blood glucose, capsaicin-sensitive sensory nerves, and central nervous system. J Pharmacol Exp Ther 1999; 289: 729.
37. Andrews JM, Rayner CK, Doran S, Hebbard GS, Horowitz M: Physiological changes in blood glucose affect appetite and pyloric motility during intraduodenal lipid infusion. Am J Physiol 1998; 275:G797-G804.
38. Chapman IM, Goble EA, Wittert GA, Morley JE, Horowitz M: Effect of intravenous glucose and euglycemic insulin infusions on short-term appetite and food intake. Am J Physiol 1998; 274:R596-R603.
39. Arneric SP, Chow SA, Long JP, Fischer LJ: Dopamine analog-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas. J Pharmacol Exp Ther 1984; 228: 551.